Ocugen Names Interim CMO as $130M Convertible Fuels Gene Therapy Push Toward FDA Filings

Ocugen has parted ways with its chief medical officer just as the biotech enters a pivotal stretch for its lead gene therapy programs. Huma Qamar left the role effective May 8, with Mohamed Genead stepping in on an interim basis. The company offered no explanation for the departure, but the timing underscores the pressure on clinical strategy, regulatory communication and data preparation as three late-stage programs race toward FDA filings.

The leadership change follows a major refinancing that bought Ocugen breathing room. On May 7, the company closed a private placement of $115 million in convertible notes, with the initial purchaser exercising its over-allotment option in full a week later for an additional $15 million. The 6.75% notes mature in 2034 and were issued at 90% of par. After discounts and expenses, net proceeds amount to roughly $112.6 million. Of that, approximately $32.7 million went to fully repay an outstanding loan from Avenue Capital, including accrued interest and prepayment penalties.

The convertible structure carries a dilution risk that the market has already priced in. Until a reserved share condition is met, conversions can only be settled in cash. After that, up to about 8.1 million new shares could be issued, with conversions possible no earlier than May 15, 2027. That limited but real overhang helps explain why the stock continues to languish. At around $1.19, the shares trade roughly 44% below the 52-week high of $2.17 and about 23% below the 50-day moving average. Over the past 30 days, the stock has fallen nearly 29.5%.

Management believes the remaining capital is sufficient to fund operations into 2028, a runway that must cover three Biologics License Applications. The most advanced candidate, OCU400, a gene therapy for retinal dystrophies, is on track to begin rolling BLA submission in the third quarter of 2026, with completion expected by the second quarter of 2027. Manufacturing qualification batches are scheduled to be finished in the second quarter of this year.

Should investors sell immediately? Or is it worth buying Ocugen?

OCU410, targeting geographic atrophy, also delivered fresh ammunition for the investment thesis. In the phase 2 ArMaDa study, the optimal dose showed a statistically significant 31% reduction in lesion growth at 12 months versus the control group. Ocugen points out that approved therapies have reported reductions of 15% and 22%, suggesting a potential clinical advantage if later data hold up. A phase 3 trial for OCU410 is slated to start in the third quarter of 2026, with a possible BLA submission by 2028.

For OCU410ST, an interim analysis of 24 patients is planned for the third quarter of this year, with topline data expected in the second quarter of 2027.

The financials reflect the heightened activity. First-quarter operating expenses climbed to $19.4 million from $16.0 million a year earlier, with R&D consuming $11.3 million and general and administrative costs $8.1 million. The net loss per share of $0.06 narrowly missed the analyst consensus of $0.05. On the revenue side, Ocugen surprised to the upside, posting $1.53 million versus expectations of roughly $500,000.

The next public checkpoint arrives in late May when Ocugen presents its gene therapy platform at the Stifel 2026 Virtual Ophthalmology Forum. Interim CMO Mohamed Genead may make his institutional investor debut there. For a company that has boosted its cash runway, cleared expensive debt and set an aggressive regulatory calendar, the forum offers an early test of whether the pipeline story can shift the narrative away from the slide in its shares.